• 제목/요약/키워드: Pancreatic Diseases

검색결과 115건 처리시간 0.022초

Effect of Prunetin on Streptozotocin-Induced Diabetic Nephropathy in Rats - a Biochemical and Molecular Approach

  • Jose Vinoth Raja Antony Samy;Nirubama Kumar;Sengottuvelu Singaravel;Rajapandiyan Krishnamoorthy;Mohammad A Alshuniaber;Mansour K. Gatasheh;Amalan Venkatesan;Vijayakumar Natesan;Sung-Jin Kim
    • Biomolecules & Therapeutics
    • /
    • 제31권6호
    • /
    • pp.619-628
    • /
    • 2023
  • In the modern era, chronic kidney failure due to diabetes has spread across the globe. Prunetin (PRU), a component of herbal medicines, has a broad variety of pharmacological activities; these may help to slow the onset of diabetic kidney disease. The anti-nephropathic effects of PRU have not yet been reported. The present study explored the potential nephroprotective actions of PRU in diabetic rats. For 28 days, nephropathic rats were given oral doses of PRU (20, 40, and 80 mg/kg). Body weight, blood urea, creatinine, total protein, lipid profile, liver marker enzymes, carbohydrate metabolic enzymes, C-reactive protein, antioxidants, lipid peroxidative indicators, and the expression of insulin receptor substrate 1 (IRS-1) and glucose transporter 2 (GLUT-2) mRNA genes were all examined. Histological examinations of the kidneys, liver, and pancreas were also performed. The oral treatment of PRU drastically lowered the blood glucose, HbA1c, blood urea, creatinine, serum glutamic-oxaloacetic transaminase, serum glutamic pyruvic transaminase, alkaline phosphatase, lipid profile, and hexokinase. Meanwhile, the levels of fructose 1,6-bisphosphatase, glucose-6-phosphatase, and phosphoenol pyruvate carboxykinase were all elevated, but glucose-6-phosphate dehydrogenase dropped significantly. Inflammatory marker antioxidants and lipid peroxidative markers were also less persistent due to this administration. PRU upregulated the IRS-1 and GLUT-2 gene expression in the nephropathic group. The possible renoprotective properties of PRU were validated by histopathology of the liver, kidney, and pancreatic tissues. It is therefore proposed that PRU (80 mg/kg) has considerable renoprotective benefits in diabetic nephropathy in rats.

Gut microbiota-generated metabolites: missing puzzles to hosts' health, diseases, and aging

  • Yan Zhang;Shibo Wei;Hang Zhang;Yunju Jo;Jong-Sun Kang;Ki-Tae Ha;Jongkil Joo;Hyun Joo Lee;Dongryeol Ryu
    • BMB Reports
    • /
    • 제57권5호
    • /
    • pp.207-215
    • /
    • 2024
  • The gut microbiota, an intricate community of bacteria residing in the gastrointestinal system, assumes a pivotal role in various physiological processes. Beyond its function in food breakdown and nutrient absorption, gut microbiota exerts a profound influence on immune and metabolic modulation by producing diverse gut microbiota-generated metabolites (GMGMs). These small molecules hold potential to impact host health via multiple pathways, which exhibit remarkable diversity, and have gained increasing attention in recent studies. Here, we elucidate the intricate implications and significant impacts of four specific metabolites, Urolithin A (UA), equol, Trimethylamine N-oxide (TMAO), and imidazole propionate, in shaping human health. Meanwhile, we also look into the advanced research on GMGMs, which demonstrate promising curative effects and hold great potential for further clinical therapies. Notably, the emergence of positive outcomes from clinical trials involving GMGMs, typified by UA, emphasizes their promising prospects in the pursuit of improved health and longevity. Collectively, the multifaceted impacts of GMGMs present intriguing avenues for future research and therapeutic interventions.

새로운 건강보험 보장성 강화 대책 2부: 복부 초음파 및 MRI 급여 확대 (A New Health Care Policy in Korea Part 2: Expansion of Coverage by National Health Insurance on the Abdominal Ultrasound and MRI)

  • 장민재;박성진
    • 대한영상의학회지
    • /
    • 제81권5호
    • /
    • pp.1069-1082
    • /
    • 2020
  • 복부 영상 영역에서는 새로운 건강보험 보장성 강화 대책으로 인하여 2018년 4월 1일 상복부 초음파, 2019년 2월 1일 하복부 초음파와 2019년 11월 1일 복부 MRI가 순서대로 급여 확대되었다. 많은 환자들이 건강보험 급여 혜택을 보게 되었으며 간경화, 담낭용종, 간선종, 이형성 결절, 췌장 낭종과 자가면역성 췌장염, 담석 등이 건강보험에 포함되었다. 그러나 급여화로 인해 각 검사의 적응증, 추적검사 가능 질환과 적용 횟수 등이 보다 복잡해졌으며 획득하여야 할 표준영상과 판독소견서의 양식이 지정되었으며, 따라서 외래나 병실에서 검사를 처방하고 검사실에서 검사를 시행할 때 주의해야 할 필요가 있다.

The Regulation of FOXP3 Expression by the Treatment of TGF-${\beta}$ and the Modification of DNA Methylation in Lung Cancer Cell Lines

  • Um, Sang-Won;Lee, Sang-Hee;Kim, Ho-Joong;Kwon, O-Jung;Kim, Hang-Rae;Kang, Jae-Seung;Lee, Wang-Jae
    • Tuberculosis and Respiratory Diseases
    • /
    • 제70권3호
    • /
    • pp.206-217
    • /
    • 2011
  • Background: Transcription factor FOXP3 characterizes the thymically derived regulatory T cells. FOXP3 is expressed by cancer cell itself and FOXP3 expression was induced by TGF-${\beta}$ treatment in pancreatic cancer cell line. However, the expression of FOXP3 expression is not well known in patients with lung cancer. This study was conducted to investigate the expression of FOXP3 in patients with lung cancer and to investigate the regulation of FOXP3 expression by the treatment of TGF-${\beta}$ and DNA methyltransferase inhibitor in lung cancer cell lines. Methods: FOXP3 expression in the tissue of patients with resected non-small cell lung cancer (NSCLC) was evaluated by immunohistochemistry. The regulation of FOXP3 expression was investigated by Western blot and RT-PCR after lung cancer cell lines were stimulated with TGF-${\beta}1$ and TGF-${\beta}2$. The regulation of FOXP3 expression was also investigated by RT-PCR and flow cytometry after lung cancer cell lines were treated with DNA methyltransferase inhibitor (5-AZA-dC). Results: FOXP3 expression was confirmed in 27% of patients with NSCLC. In NCI-H460 cell line, TGF-${\beta}2$ decreased FOXP3 mRNA and protein expressions. In A549 cell line, both TGF-${\beta}1$ and TGF-${\beta}2$ decreased FOXP3 mRNA and protein expressions. 5-AZA-dC increased FOXP3 mRNA expression in NCI-H460 and A549 cell lines. Moreover, 5-AZA-dC increased intracellular FOXP3 protein expression in A549 cell lines. Conclusion: It was shown that FOXP3 is expressed by cancer cell itself in patients with NSCLC. Treatment of TGF-${\beta}2$ and DNA methyltransferase inhibitor seems to be associated with the regulation of FOXP3 expression in lung cancer cell lines.

Normalization of Elevated CA 19-9 Level after Treatment in a Patient with the Nodular Bronchiectatic Form of Mycobacterium abscessus Lung Disease

  • Chang, Boksoon;Han, Seo Goo;Kim, Wooyoul;Ko, Yousang;Song, Junwhi;Hong, Goohyeon;Eom, Jung Seop;Lee, Ji Hyun;Jhun, Byung Woo;Koh, Won-Jung
    • Tuberculosis and Respiratory Diseases
    • /
    • 제75권1호
    • /
    • pp.25-27
    • /
    • 2013
  • Carbohydrate antigen 19-9 (CA 19-9) is a widely-used tumor marker in patients with pancreatic cancer. However, some patients with respiratory disease also exhibit elevated serum CA 19-9 levels. We report a case of normalization of elevated serum CA 19-9 levels after treatment of the nodular bronchiectatic form of Mycobacterium abscessus lung disease. A 40-year-old man visited our hospital because of chronic cough and sputum. A computed tomography scan revealed severe bronchiectasis in the right upper and right middle lobes. Nontuberculous mycobacteria were repeatedly isolated and identified as M. abscessus. The serum CA 19-9 level was elevated to 142.35 U/mL (normal range, <37 U/mL). Surgical resection was performed because of failure of sputum conversion after antibiotic treatment. The serum CA 19-9 level returned to the normal range after surgery. This case suggested that serum CA 19-9 levels could be elevated in patients with the nodular bronchiectatic form of M. abscessus lung disease.

CA 19-9 방사면역측정법의 기본적 검토 및 악성종양환자에서의 혈청 CA 19-9치의 임상적 의의에 관한 연구 (Performance Characteristics of CA 19-9 Radioimmunoassay and Clinical Significance of Serum CA 19-9 Assay in Patients with Malignancy)

  • 김상은;송영기;조보연;김노경;고창순;이문호;홍성운;홍기석
    • 대한핵의학회지
    • /
    • 제19권1호
    • /
    • pp.119-126
    • /
    • 1985
  • To evaluate the performance characteristics of CA 19-9 radioimmunoassay and the clinical significance of serum CA 19-9 assay in patients with malignancy, serum CA 19-9 levels were measured by radioimmunoassay using monoclonal antibody in 135 normal controls, 81 patients with various untreated malignancy, 9 patients of postoperative colon cancer without recurrence and 20 patients with benign gastrointestinal diseases, who visited Seoul National University Hospital from June, 1984 to March, 1985. The results were as follows; 1) The CA 19-9 radioimmunoassay was simple to perform and can be completed in one work day. And the between-assay reproducibility and the assay recovery were both excellent. 2) The mean serum CA 19-9 level in 135 normal controls was $8.4{\pm}4.2U/mL$. Normal upper limit of serum CA 19-9 was defined as 21.0 U/mL. 4 out of 135(3.0%) normal controls showed elevated CA 19-9 levels above the normal upper limit. 3) One out of 20(5.0%) patients with benign gastrointestinal diseases showed elevated serum CA 19-9 level above the normal upper limit. 4) In 81 patients with various' untreated malignancy, 41 patients(50.6%) showed elevated serum CA 19-9 levels. 66.7% of 18 patients with colorectal cancer, 100% of 2 patients with pancreatic cancer, 100% of 3 patients with common bile duct cancer, 47.1% of 17 patients with stomach cancer, 28.6% of 28 patients with hepatoma and 60.0% of 5 other gastrointestinal tract cancers showed elevated serum CA 19-9 levels. 5) The sensitivities of serum CA 19-9 related to resectability in colorectal and stomach cancer were 33.3% in resectable colorectal cancer, 83.3% in unresectable colorectal cancer, 41.7% in resectable stomach cancer, 60.0% in unresectable stomach cancer respectively. 6) The sensitivity of serum CA 19-9 in 9 patients of postoperative colorectal cancer without recurrence were 33.3% and significantly decreased compared with that of untreated colorectal cancer, 66.7% (p<0.05). 7) In patients with colorectal cancer, simultaneous measurement of serum CA 19-9 and serum CEA levels increased sensitivities. From above results, we concluded that serum CA 19-9 radioimmunoassay is simple to perform and reproducible, and is a useful indicator reflecting tumor extent and responses to the treatment in patients with malignancy.

  • PDF

담관낭종 -대한소아외과학회회원 대상 전국조사- (Choledochal Cyst in Korea - A Survey by the Korean Association of Pediatric Surgeons -)

  • 최금자;김대연;김상윤;김성철;김신곤;김우기;김인구;김재억;김재천;김해영;김홍주;박귀원;박우현;박진영;백홍규;서정민;송영택;오수명;유수영;이두선;이명덕;이석구;이성철;박영식;이태훈;정상영
    • Advances in pediatric surgery
    • /
    • 제9권1호
    • /
    • pp.45-51
    • /
    • 2003
  • 본 조사 결과는 32개 병원의 39명의 회원에 의해 수술받은 환자 348명의 기록과 회원 37명의 설문 응답자를 분석한 것으로 많은 수의 기록지가 내용이 불충분하거나 일치되지 않은 기술로 인해 자료로서의 한계가 있었다. 특히 췌담관합류 이상에 대한 기록 중 약 절반이 미상으로 기록된 것에서 알 수 있드시 자료가 매우 미흡하였고, 담관낭종의 유형을 정하는 것 예후 인자 및 산 전 진단된 담관낭종의 수술 적기등에 대하여도 회원마다 견해 차이가 있으나 심도있는 토론이 이루어지지 않았다. 따라서 이 결과를 외국의 통계 분석과 비교하는 것 보다는 회원들의 향 후 진료와 연구에 참고가 될 수 있다는 것에 의미를 두고자 하며, 회원들이 동일한 등록지를 작성하는 전향적 연구로 우리나라 담관낭종에 대한 분류, 췌담관 합류이상, 예후 인자들에 대한 재 논의의 출발점이 되기를 기대한다.

  • PDF

제2형 당뇨모델 db/db 마우스에서 밀순 물추출물의 항당뇨 효과 (Anti-diabetic Effects of Triticum aestivum L. Water Extracts in db/db Mice as an Animal Model of Diabetes Mellitus Type II)

  • 이선희;임성원;이영미;허정무;이회선;김대기
    • 생약학회지
    • /
    • 제41권4호
    • /
    • pp.282-288
    • /
    • 2010
  • We evaluated the anti-diabetic effects of Triticum aestivum sprout water extract (TA) in diabetes mellitus type 2. For the experiments, the diabetic animal model db/db mice were divided to 3 groups: diabetic control (db/db) and two experimental groups orally treated with 25 and 100 mg/kg single dose of TA (TA-25 and TA-100, respectively). The lean mice were used as the non-diabetic normal control. All mice have free access to water and AIN-93 diet. TA was administrated to diabetic mice for 5 weeks and the diabetic clinical markers, including blood glucose level, body weight, food intake and insulin level, were measured at a time. After administration for 5 weeks, the blood glucose level was decreased 1.10 and 1.98 folds in TA-25 and TA-100 groups, respectively, compared with db/db group. The body weight and diet consumption were significantly reduced by TA treatment in dose-dependent manner. The treatments of TA-100 also significantly decreased remarkedly liver weight and slightly serum insulin levels when compared with them of the diabetic control group. However the immunohistochemical staining for insulin clearly showed high expression of insulin in the pancreatic islet cells derived from all db/db mice, even if TA was administrated. Moreover, TA-100 treatment significantly improved impaired glucose tolerance in diabetic db/db mice. The results suggest that TA has anti-hyperglycemic effect attenuating blood glucose in the animal model of type 2 diabetes and might be useful as a functional diet for human diabetic diseases.

Lipopolysaccharide로 자극한 RAW 264.7 세포에서 성체줄기세포 유래 엑소좀(exosome)의 면역 조절 효과 (Immunomodulatory Effect of Mesenchymal Stem Cell-Derived Exosomes in Lipopolysaccharide-Stimulated RAW 264.7 Cells)

  • 정수경;박미정;이지현;변정수;구나연;조인수;차상호
    • 한국미생물·생명공학회지
    • /
    • 제44권3호
    • /
    • pp.383-390
    • /
    • 2016
  • 본 연구는 대식세포에서 LPS를 이용하여 염증 유사 세포 모델을 만들고 염증 유사 대식세포 모델에서 성체줄기세포의 면역 조절 능력을 평가하였다. LPS 자극에 의해 증가된 IL-1β, TNF-α 및 IL-10의 생성은 성체줄기세포를 공배양한 실험군 뿐만 아니라 성체줄기세포를 배양한 상층 배양액을 처리한 실험군에서도 동일한 효과를 나타내었으며, 또한 성체줄기세포 유래 엑소좀을 염증 유사 대식세포 모델에 처리하여 유사한 결과를 관찰하였다. 이 결과는 성체줄기세포 자체의 염증 억제 기능보다는 성체줄기세포 유래 엑소좀을 포함하여 성체줄기세포가 분비하는 bioactive molecules에 의해 세포 간 신호 전달이 이루어지고 있음을 의미하며, 이러한 엑소좀은 염증 관련 질환 분야에 치료적 적용이 가능하고 또한 새로운 염증 치료제 개발의 툴로 사용될 수 있음을 시사한다.

사망 원인별 유형 분석을 통한 사망자의 위생 관리에 대한 연구 (Study on Sanitary Management of Deceased Bodies through Categorical Analysis of Cause of Death)

  • 최정목
    • 한국콘텐츠학회논문지
    • /
    • 제17권7호
    • /
    • pp.265-275
    • /
    • 2017
  • 본 연구는 장례식장에서 사망자를 위생적으로 관리하기 위해 사망의 장소, 종류 및 원인 등 사망자들의 유형에 따라 체액 분출 등 사후 어떤 변화가 있는지 알아보고자 하였다. 사망자 858명을 대상으로 조사한 결과 평균 연령은 68.6세이며, 주요 사망의 원인은 83.0%가 병사이며, 사망 장소는 79.5%가 의료기관에서 발생되었다. 사망자에서 발생되는 체액 분출율은 전체 사망자의 46.2%에서 조사되었고, 사망의 종류에 따라서는 사고사가 78.8%로 가장 높고, 노화사는 10.8%로 가장 낮았다. 사망의 장소에 따른 의료기관 사망자는 46.3%, 주택 사망자는 38.6%인데 반해 기타 장소는 77.4%로 높았다. 사망의 원인으로 직접, 중간 및 선행 사인이 기록된 사망자 수는 크게 다르지만 체액 분출 비율은 비슷하였다. 장기 및 계통별 사망자 수는 직접, 중간 및 선행 사인 모두 호흡기질환과 심장질환 사망자 수가 가장 많고, 체액 분출은 직접 사인은 간질환 사망자가 가장 높고 소화기 및 혈액순환계 순이며, 중간 및 선행 사인에서는 기타 및 사고사가 가장 높은 비율을 보였다. 사망의 원인에 기록된 질병을 기준으로 한 사망자 수는 직접 사인은 심폐부전이 96명으로 가장 많고 폐렴 및 패혈증 순이며, 체액 분출은 사망자 수가 15명 이상 기준으로 담관암(73.3%)이 가장 높고, 췌장암, 중증뇌손상 및 간암 순으로 많았다. 따라서 사망자의 위생적 관리를 위해서는 보다 정확한 질병명과 발병기간을 명시하도록 하여야 하고, 사망자 이송과정에서는 관련 정보가 문서화 되고 체계적인 전달 시스템이 될 수 있도록 제도화 하여야 할 것이다.